Coronavirus-treatment-updates
The
FDA has authorized use of the nirmatrelvir/ritonavir, for the treatment of mild
to moderate COVID-19. Studies have indicated that it is 88% effective at
preventing hospitalization and death from COVID-19.
Criteria
for Prescribing
To prescribe nirmatrelvir/ritonavir,
prescribers should confirm that the following criteria have been...
Journal of the American Heart Association: published
on Jun 2022
COVID‐19 is an infectious illness,
with an increased risk of thromboembolism. The overall rate of venous
thromboembolism and arterial thromboembolism among patients with COVID‐19 is
21% and 2%, respectively.
Therefore, this complication
represents an important therapeut...
Clinical Infectious Diseases: An Official Publication of the Infectious
Diseases Society of America: Published on June 2022
COVID rebound has been reported to
occur 2 to 8 days after initial recovery and is characterized by a recurrence
of COVID-19 symptoms or a positive viral test after having tested negative. The
CDC recommends that he...
European Heart Journal:
Management of
cardiometabolic risk factors should become a priority for physicians. The
long-term impact of COVID-19 on cardiovascular (CV) health and mortality is
also emerging as a major global concern.
Non-pharmacological
supportive approaches:
The management of long COVID tends to be
largely supportive....
The rapidly escalating coronavirus
disease 2019 (COVID-19) pandemic has focused attention on the diagnosis and
treatment of patients with acute respiratory infection in an unprecedented
manner. Although most of the lung injury patients have is believed to be caused
by the virus, concern over bacterial co-infection also informs current
treatmen...
COVID-19 Update:In light of the most recent
information and data available, today, the FDA revised the authorizations for
two monoclonal antibody treatments – bamlanivimab
and etesevimab (administered together) and casirivimab and imdevimab – to limit their use to only when the
patient is likely to have been infected with or exposed to a varian...
The U.S. Food and Drug
Administration authorized Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir
tablets, co-packaged for oral use) for emergency use for the treatment of
mild-to-moderate coronavirus disease in adults and children 12 years and older weighing
at least 40 kilograms with positive results of direct SARS-CoV-2 testing, and who...
The U.S. Food and Drug
Administration revised the emergency use authorization (EUA) of bamlanivimab
and etesevimab monoclonal antibodies (previously authorized for pediatric
patients 12 years of age and older weighing at least 40 kilograms, or about 88
pounds), to additionally authorize bamlanivimab and etesivimab administered
together for the...
Sotrovimab has been approved for patients with mild-to-moderate
COVID-19 who are at high risk of developing severe disease.The Medicines and Healthcare
products Regulatory Agency (MHRA) has approved the monoclonal antibody
treatment Sotrovimab (Xevudy; GSK and Vir Biotechnology) for people with
mild-to-moderate COVID-19 and at least one risk fa...
AZD7442 is a combination of two
long-acting antibodies (LAABs) - Tixagevimab and Cilgavimab - derived from B-cells donated by convalescent patients after SARS-CoV-2 virus.The AstraZeneca drug AZD7442, has
been undergoing final stage clinical trials to assess its safety and efficacy. AstraZeneca’s
antibody treatment has been shown to be highly ef...
Britain authorizes Merck’s Molnupiravir,
the world’s first approval of oral covid-19 treatment pill. The drug is waiting
for FDA review and approval. Britain became the first country in the
world to approve a potentially game-changing Covid-19 antiviral pill jointly
developed by US drugmaker Merck and Ridgeback Biotherapeutics, i...
A new draft recommendation
relating to anticoagulation for discharged patients with COVID-19 has
been issued by the American Society of Hematology (ASH).For patients with COVID-19 who
are being discharged from the hospital and who do not have suspected or
confirmed venous thromboembolism or another indication for anticoagulation, the
ASH guide...
